Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00350831 · ClinicalTrials.gov registry record · Phase 1
Study of XL820 Given Orally Daily to Subjects With Solid Tumors
A Phase 1 study, sponsored by Exelixis.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT00350831 is a Phase 1 study that has completed, run by Exelixis. The registered enrollment target is 30 participants.
The verdict
NCT00350831, a Phase 1 study, has completed, sponsored by Exelixis.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and tolerability of the KIT inhibitor XL820 when given orally daily to adults with advanced solid tumors.
Interventions
- DRUG XL820
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2006-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00350831
The ClinicalTrials.gov registry entry for NCT00350831 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Exelixis, which has 48 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which XL820 is the first listed.
NCT00350831 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00350831 about?
NCT00350831 is a clinical study titled "Study of XL820 Given Orally Daily to Subjects With Solid Tumors". The purpose of this study is to assess the safety and tolerability of the KIT inhibitor XL820 when given orally daily to adults with advanced solid tumors.
What is the current status of trial NCT00350831?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2006-07.
What interventions are being tested in trial NCT00350831?
The interventions under investigation include: XL820 (DRUG).
Who is sponsoring clinical trial NCT00350831?
This trial is sponsored by Exelixis, which has 48 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.